Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 12/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678634 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7674992 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7670221 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7675887 | 1.00 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7670196 | 0.96 | ADRB3 (0.92) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7670192 | 0.96 | ADRB3 (0.92) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7671776 | 0.95 | ADRB3 (0.91) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7671775 | 0.95 | ADRB3 (0.91) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7674878 | 0.95 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7672256 | 0.95 | ADRB3 (1.00) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436914-B1 | TREATING DIABETES, OBESITY, DEPRESSION, ACHALASIA OR INTESTINAL HYPERMOTILITY DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-20 | — | — | US | claimed |
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | SHER PHILIP M (US) | 2002-02-28 | — | — | US | claimed |
| US-6436914-B1 | TREATING DIABETES, OBESITY, DEPRESSION, ACHALASIA OR INTESTINAL HYPERMOTILITY DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-20 | — | — | US | disclosed |
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | SHER PHILIP M (US) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | ADRB3, ADRB1, ADRA1A | ADRB3 1/4885ADRB2 4/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.